| Literature DB >> 32615966 |
Nabeel Khan1, Ken McGarry2, Atta Abbas Naqvi3, Muhammad Shahid Iqbal4, Zaki Haider5.
Abstract
BACKGROUND: Pharmacy service is an essential part of a healthcare system. The profession of pharmacy is well recognized and is practiced to its full potential in developed countries however, it is underutilized in developing countries such as Pakistan. The recognition of pharmacist's role as healthcare professional is limited. This study aimed to document pharmacists' attitude towards their role in Pakistan's healthcare system, their experience with doctors and their perceptions towards involvement in medicines management.Entities:
Keywords: Clinical pharmacists; Clinical pharmacy service; Hospital pharmacy service; Pakistan; Pharmacists
Year: 2020 PMID: 32615966 PMCID: PMC7330985 DOI: 10.1186/s12913-020-05459-0
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Study venues
Participants’ information (N = 396)
| Characteristics | N (%) |
|---|---|
| Male | 254 (64.1%) |
| Female | 142 (35.9%) |
| Bachelor of Pharmacy/ Master of Pharmacy | 87 (22%) |
| Doctor of Pharmacy (Pharm.D) | 295 (74.5%) |
| Overseas Qualification | 14 (3.5%) |
| State Funded Hospital | 199 (50.3%) |
| Private Hospital | 197 (49.7%) |
| Pharmacist | 363 (91.7%) |
| Senior Pharmacist | 26 (6.6%) |
| Chief Pharmacist | 7 (1.8%) |
| Less than 5 years | 68 (17.2%) |
| 5–10 years | 236 (59.6%) |
| More than 10 years | 92 (23.2%) |
| Inpatient | 265 (66.9%) |
| Outpatient | 105 (26.5%) |
| Oncology pharmacy | 26 (6.6%) |
| Sindh | 143 (36.1%) |
| Punjab | 175 (44.2%) |
| Baluchistan | 9 (2.3%) |
| KPK | 44 (11.1%) |
| Capital Territory | 17 (4.3%) |
| AJK | 8 (2.0%) |
| Yes | 393 (99.2%) |
| In process | 3 (0.8%) |
KPK Khyber Pakhtunkhwa, AJK Azad Jammu and Kashmir
Attitude of pharmacist regarding their role in the healthcare system (N = 396)
| Roles | Education | Agree | Disagree | Type | Agree | Disagree | Experience | Agree | Disagree | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| To educate patients and carers about the safe and appropriate use of medicines | B/M Pharm | 71 (17.9%) | 16 (4%) | 0.000* | State funded | 172 (43.4%) | 27 (6.8%) | 0.035 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.001 |
| Pharm.D | 275 (69.4%) | 20 (5.1%) | Private | 183 (46.2%) | 14 (3.5%) | 5–10 years | 217 (54.8%) | 19 (4.8%) | ||||
| Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 73 (18.4%) | 19 (4.8%) | ||||
| To monitor and report patients’ response to drug therapy | B/M Pharm | 74 (18.7%) | 13 (3.3%) | 0.002 | State funded | 176 (44.4%) | 23 (5.8%) | 0.086 | < 5 years | 64 (16.2%) | 4 (1.0%) | 0.022 |
| Pharm.D | 276 (69.7%) | 19 (4.8%) | Private | 184 (46.5%) | 13 (3.3%) | 5–10 years | 219 (55.3%) | 17 (4.3%) | ||||
| Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 77 (19.4%) | 15 (3.8%) | ||||
| To be available for clinician consultation during ward rounds | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.031 | State funded | 169 (42.7%) | 30 (7.6%) | 0.031 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.009 |
| Pharm.D | 268 (67.1%) | 27 (6.8%) | Private | 181 (45.7%) | 16 (4%) | 5–10 years | 211 (53.3%) | 25 (6.3%) | ||||
| Overseas | 11 (2.8%) | 3 (0.8%) | – | – | – | > 10 years | 74 (18.7%) | 18 (4.5%) | ||||
| To communicate or liaise with other healthcare professionals delivering patient care to facilitate positive health outcomes | B/M Pharm | 78 (19.7%) | 9 (2.3%) | 0.005 | State funded | 193 (48.7%) | 6 (1.5%) | 0.000* | < 5 years | 67 (16.9%) | 1 (0.3%) | 0.031 |
| Pharm.D | 269 (67.9%) | 26 (6.6%) | Private | 163 (41.2%) | 34 (8.6%) | 5–10 years | 209 (52.8%) | 27 (6.8%) | ||||
| Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 80 (20.2%) | 12 (3.0%) | ||||
| To collaborate with other healthcare professionals as part of a multidisciplinary team | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.001 | State funded | 172 (43.4%) | 27 (6.8%) | 0.293 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.001 |
| Pharm.D | 269 (67.9%) | 26 (5.5%) | Private | 177 (44.7%) | 20 (5.1%) | 5–10 years | 213 (53.8%) | 23 (5.8%) | ||||
| Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 71 (17.9%) | 21 (5.3%) | ||||
| To provide advice to patients about their medication/s and/or health conditions | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.000* | State funded | 175 (44.2%) | 24 (6.1%) | 0.083 | < 5 years | 64 (16.2%) | 4 (1.0%) | 0.000* |
| Pharm.D | 278 (70.2%) | 17 (4.3%) | Private | 184 (46.5%) | 13 (3.3%) | 5–10 years | 222 (56.1%) | 14 (3.5%) | ||||
| Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 73 (18.4%) | 19 (4.8%) | ||||
| To dispense and check supply of medicines to patient (counting pills, labelling, and accuracy checking) | B/M Pharm | 67 (16.9%) | 20 (5.1%) | 0.036 | State funded | 161 (40.7%) | 38 (9.6%) | 0.018 | < 5 years | 63 (15.9%) | 5 (1.3%) | 0.021 |
| Pharm.D | 259 (65.4%) | 36 (9.1%) | Private | 176 (44.4%) | 21 (5.3%) | 5–10 years | 203 (51.3%) | 33 (8.3%) | ||||
| Overseas | 11 (2.8%) | 3 (0.8%) | – | – | – | > 10 years | 71 (17.9%) | 21 (5.3%) | ||||
| To provide a “closed shop” service: receiving prescriptions from a practitioner and dispense medicine to a patient only | B/M Pharm | 11 (2.8%) | 76 (19.2%) | 0.001 | State funded | 54 (13.6%) | 145 (36.6%) | 0.000 | < 5 years | 16 (4.0%) | 52 (13.1%) | 0.623 |
| Pharm.D | 59 (14.9%) | 236 (59.6%) | Private | 24 (6.1%) | 173 (43.7%) | 5–10 years | 46 (11.6%) | 190 (48.0%) | ||||
| Overseas | 8 (2.0%) | 6 (1.5%) | – | – | – | > 10 years | 16 (4.0%) | 76 (19.2%) | ||||
| To check that prescriptions are written for the correct dose for the patient | B/M Pharm | 60 (15.2%) | 27 (6.8%) | 0.000* | State funded | 152 (38.4%) | 47 (11.9%) | 0.955 | < 5 years | 52 (13.1%) | 16 (4.0%) | 0.014 |
| Pharm.D | 239 (60.4%) | 56 (14.1%) | Private | 150 (37.9%) | 47 (11.9%) | 5–10 years | 190 (48.0%) | 46 (11.6%) | ||||
| Overseas | 3 (0.8%) | 11 (2.8%) | – | – | – | > 10 years | 60 (15.2%) | 32 (8.1%) | ||||
| To check that prescriptions do not have any drug-drug interactions | B/M Pharm | 55 (13.9%) | 32 (8.1%) | 0.017 | State funded | 156 (39.4%) | 43 (10.9%) | 0.093 | < 5 years | 61 (15.4%) | 7 (1.8%) | 0.004 |
| Pharm.D | 231 (58.3%) | 64 (16.2%) | Private | 140 (35.4%) | 57 (14.4%) | 5–10 years | 173 (43.7%) | 63 (15.9%) | ||||
| Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 62 (15.7%) | 30 (7.6%) | ||||
| To check that a prescription is not contraindicated for the patient | B/M Pharm | 67 (16.9%) | 20 (5.1%) | 0.036 | State funded | 161 (40.7%) | 38 (9.6%) | 0.018 | < 5 years | 63 (15.9%) | 5 (1.3%) | 0.021 |
| Pharm.D | 259 (65.4%) | 36 (9.1%) | Private | 176 (44.4%) | 21 (5.3%) | 5–10 years | 203 (51.3%) | 33 (8.3%) | ||||
| Overseas | 11 (2.8%) | 3 (0.8%) | – | – | – | > 10 years | 71 (17.9%) | 21 (5.3%) | ||||
| To advise clinicians and others about the cost-effectiveness of medicines | B/M Pharm | 74 (18.7%) | 13 (3.3%) | 0.002 | State funded | 176 (44.4%) | 23 (5.8%) | 0.086 | < 5 years | 64 (16.2%) | 4 (1.0%) | 0.022 |
| Pharm.D | 276 (69.7%) | 19 (4.8%) | Private | 184 (46.5%) | 13 (3.3%) | 5–10 years | 219 (55.3%) | 17 (4.3%) | ||||
| Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 77 (19.4%) | 15 (3.8%) | ||||
| To formally review a patient’s therapy and to make necessary changes to help promote positive health outcomes | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.031 | State funded | 169 (42.7%) | 30 (7.6%) | 0.031 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.009 |
| Pharm.D | 268 (67.7%) | 27 (6.8%) | Private | 181 (45.7%) | 16 (4.0%) | 5–10 years | 211 (53.3%) | 25 (6.3%) | ||||
| Overseas | 11 (2.8%) | 3 (0.8%) | – | – | – | > 10 years | 74 (18.7%) | 18 (4.5%) | ||||
| To supervise repeat prescriptions for patients according to agreed protocols | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.000* | State funded | 172 (43.4%) | 27 (6.8%) | 0.035 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.001 |
| Pharm.D | 275 (69.5) | 20 (5.1%) | Private | 183 (46.2%) | 14 (3.5%) | 5–10 years | 217 (54.8%) | 19 (4.8%) | ||||
| Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 73 (18.4%) | 19 (4.8%) | ||||
| To make dose adjustments to a patient’s medicine using protocols established with prescribers | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.000* | State funded | 175 (44.2%) | 24 (6.1%) | 0.062 | < 5 years | 64 (16.2%) | 4 (1.0%) | 0.000* |
| Pharm.D | 278 (70.2%) | 17 (4.3%) | Private | 184 (46.5%) | 13 (3.3%) | 5–10 years | 222 (56.1%) | 14 (3.5%) | ||||
| Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 73 (18.4%) | 19 (4.8%) | ||||
| To prescribe therapy for a patient following a clinician’s diagnosis (partnership or supplementary prescribing) | B/M Pharm | 79 (19.9%) | 8 (2.0%) | 0.001 | State funded | 187 (47.2%) | 12 (3.0%) | 0.816 | < 5 years | 66 (16.7%) | 2 (0.5%0 | 0.032 |
| Pharm.D | 282 (71.2) | 13 (3.3%) | Private | 184 (46.5%) | 13 (3.3%) | 5–10 years | 224 (56.6%) | 12 (3.0%) | ||||
| Overseas | 10 (2/5%) | 4 (1.0%) | – | – | – | > 10 years | 81 (20.5%) | 11 (2.8%) | ||||
| To prescribe therapy for a patient independent of clinician’s diagnosis following an initial patient assessment (independent prescribing) | B/M Pharm | 55 (13.9%) | 32 (8.1%) | 0.017 | State funded | 156 (39.4%) | 43 (10.9%) | 0.093 | < 5 years | 61 (15.4%) | 7 (1.8%) | 0.004 |
| Pharm.D | 231 (58.7%) | 64 (16.2%) | Private | 140 (35.4%) | 57 (14.4%) | 5–10 years | 173 (43.7%) | 63 (15.9%) | ||||
| Overseas | 10 (2.5%) | 4 (1.0%) | – | – | – | > 10 years | 62 (15.7%) | 30 (7.6%) |
* = significant p-value with Cramer V
Experience of pharmacists with doctors (N = 396)
| Experience | Education | Agree | Disagree | Type | Agree | Disagree | Experience | Agree | Disagree | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacists are a reliable source of general medicines information (i.e., specific facts about medicines, which can be found in standard references) | B/M Pharm | 70 (17.7%) | 17 (4.3%) | 0.000* | State funded | 180 (45.5%) | 19 (4.8%) | 0.016 | < 5 years | 68 (17.2%) | 0 (0%) | 0.000* |
| Pharm.D | 286 (72.2%) | 9 (2.3%) | Private | 190 (48%) | 7 (1.8%) | 5–10 years | 224 (56.6%) | 12 (3.0%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 78 (19.7%) | 14 (3.5%) | ||||
| Pharmacists routinely counsel patients regarding the safe and appropriate use of medicines | B/M Pharm | 72 (18.2%) | 15 (3.8%) | 0.002 | State funded | 181 (45.7%) | 18 (4.5%) | 0.606 | < 5 years | 64 (16.2%) | 4 (1.0%) | 0.007 |
| Pharm.D | 277 (69.9%) | 18 (4.5%) | Private | 182 (46%) | 15 (3.8%) | 5–10 years | 222 (56.1%) | 14 (3.5%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 77 (19.4%) | 15 (3.8%) | ||||
| Pharmacists routinely inform clinicians about the cost-effectiveness of therapy and give accurate advice regarding alternatives treatments | B/M Pharm | 55 (13.9%) | 32 (8.1%) | 0.000* | State funded | 171 (43.2%) | 28 (7.1%) | 0.005 | < 5 years | 63 (15.9%) | 5 (1.3%) | 0.004 |
| Pharm.D | 249 (62.9%) | 46 (11.6%) | Private | 147 (37.1%) | 50 (12.6%) | 5–10 years | 189 (47.7%) | 47 (11.9%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 66 (16.7%) | 26 (6.6%) | ||||
| Pharmacists are willing to take personal responsibility for resolving any medicines-related problems they discover | B/M Pharm | 73 (18.4%) | 14 (3.5%) | 0.000* | State funded | 180 (45.5%) | 19 (4.8%) | 0.008 | < 5 years | 67 (16.9%) | 1 (0.3%) | 0.001 |
| Pharm.D | 284 (71.7%) | 11 (2.8%) | Private | 191 (48.2%) | 6 (1.5%) | 5–10 years | 225 (56.8%) | 11 (2.8%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 79 (19.9% | 13 (3.3%) | ||||
| Pharmacists routinely inform clinicians if they discover clinical problems with prescriptions | B/M Pharm | 78 (19.7%) | 9 (2.3%) | 0.005 | State funded | 193 (48.7%) | 6 (1.5%) | 0.000* | < 5 years | 67 (16.9%) | 1 (0.3%) | 0.031 |
| Pharm.D | 269 (67.9%) | 26 (6.6%) | Private | 163 (41.2%) | 34 (8.6%) | 5–10 years | 209 (52.8%) | 27 (6.8%) | ||||
| Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 80 (20.2%) | 12 (3.0%) | ||||
| Pharmacists frequently ask to clarify therapeutic objectives clinicians have for patients | B/M Pharm | 56 (14.1%) | 31 (7.8%) | 0.000* | State funded | 169 (42.7%) | 30 (7.6%) | 0.047 | < 5 years | 64 (16.2%) | 4 (1.0%) | 0.000* |
| Pharm.D | 279 (70.5%) | 16 (4.0%) | Private | 180 (45.5%) | 17 (4.3%) | 5–10 years | 220 (55.6%) | 16 (4.0%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 65 (16.4%) | 27 (6.8%) | ||||
| Pharmacists frequently let medics know that patients have experienced some problem with their medications | B/M Pharm | 71 (17.9%) | 16 (4.0%) | 0.000* | State funded | 172 (43.4%) | 27 (6.8%) | 0.035 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.001 |
| Pharm.D | 275 (69.4%) | 20 (5.1%) | Private | 183 (46.2%) | 14 (3.5%) | 5–10 years | 217 (54.8%) | 19 (4.8%) | ||||
| Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 73 (18.4%) | 19 (4.8%) | ||||
| Pharmacists are focused on ensuring the safety of patients with respect to the therapeutic use of medicines | B/M Pharm | 70 (17.7%) | 17 (4.3%) | 0.014 | State funded | 184 (46.5%) | 15 (3.8%) | 0.023 | < 5 years | 66 (16.7%) | 2 (0.5%) | 0.008 |
| Pharm.D | 270 (68.2%) | 25 (6.3%) | Private | 168 (42.4%) | 29 (7.3%) | 5–10 years | 211 (53.3%) | 25 (6.3%) | ||||
| Overseas | 12 (3.0%) | 2 (0.5%) | – | – | – | > 10 years | 75 (18.9%) | 17 (4.3%) | ||||
| Pharmacists respect the autonomy of patients and act to promote the concept of concordance | B/M Pharm | 73 (18.4%) | 14 (3.5%) | 0.000* | State funded | 181 (45.7%) | 18 (4.5%) | 0.025 | < 5 years | 66 (16.7%) | 2 (0.5%) | 0.002 |
| Pharm.D | 284 (71.7%) | 11 (2.8%) | Private | 190 (48%) | 7 (1.8%) | 5–10 years | 226 (57.1%) | 10 (2.5%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 79 (19.9%) | 13 (3.3%) | ||||
| Pharmacists are practicing as autonomous clinicians | B/M Pharm | 77 (19.4%) | 10 (2.5%) | 0.005 | State funded | 173 (43.7%) | 26 (6.6%) | 0.075 | < 5 years | 65 (16.4%) | 3 (0.8%) | 0.021 |
| Pharm.D | 269 (67.9%) | 26 (6.6%) | Private | 182 (46%) | 15 (3.8%) | 5–10 years | 214 (54.0%) | 22 (5.6%) | ||||
| Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 76 (19.2%) | 16 (4.0%) |
* = significant p-value with Cramer V
Perception of pharmacists regarding their involvement in medicines management (N = 396)
| Perceptions | Education | Agree | Disagree | Type | Agree | Disagree | Experience | Agree | Disagree | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacists should increase their involvement in medicines management | B/M Pharm | 45 (11.4%) | 42 (10.6%) | 0.000* | State funded | 135 (34.1%) | 64 (16.2%) | 0.028 | < 5 years | 54 (13.6%) | 14 (3.5%) | 0.000* |
| Pharm.D | 229 (57.8%) | 66 (16.7%) | Private | 153 (38.6%) | 44 (11.1%) | 5–10 years | 182 (46.0%) | 54 (13.6%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 52 (13.1%) | 40 (10.1%) | ||||
| Current state or private funding does not support collaborative work between pharmacists and clinicians in medicines management | B/M Pharm | 75 (18.9%) | 12 (3.0%) | 0.004 | State funded | 181 (45.7%) | 18 (4.5%) | 0.025 | < 5 years | 60 (15.2%) | 8 (2.0%) | 0.004 |
| Pharm.D | 282 (71.2%) | 13 (3.3%) | Private | 190 (48%) | 7 (1.8%) | 5–10 years | 229 (57.8%) | 7 (1.8%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 82 (20.7%) | 10 (2.5%) | ||||
| Other than dispensing prescriptions, pharmacists are on the periphery of the core healthcare team | B/M Pharm | 69 (17.4%) | 18 (4.5%) | 0.000* | State funded | 189 (47.7%) | 10 (2.5%) | 0.804 | < 5 years | 67 (16.9%) | 1 (0.3%) | 0.000* |
| Pharm.D | 292 (73.7%) | 3 (0.8%) | Private | 186 (47%) | 11 (2.8%) | 5–10 years | 230 (58.1%) | 6 (1.5%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 78 (19.7%) | 14 (3.5%) | ||||
| Clinicians do not want pharmacists to provide medicines management services | B/M Pharm | 63 (15.9%) | 24 (6.1%) | 0.000* | State funded | 163 (41.2%) | 36 (9.1%) | 0.006 | < 5 years | 58 (14.6%) | 10 (2.5%) | 0.000* |
| Pharm.D | 273 (68.9%) | 22 (5.6%) | Private | 180 (45.5%) | 17 (4.3%) | 5–10 years | 217 (54.8%) | 19 (4.8%) | ||||
| Overseas | 7 (1.8%) | 7 (1.8%) | – | – | – | > 10 years | 68 (17.2%) | 24 (6.1%) | ||||
| Patients would not subscribe to enhanced pharmacy practice services | B/M Pharm | 38 (9.6%) | 49 (12.4%) | 0.000* | State funded | 156 (39.4%) | 43 (10.9%) | 0.002 | < 5 years | 66 (16.7%) | 2 (0.5%) | 0.000* |
| Pharm.D | 281 (71.0%) | 14 (3.5%) | Private | 177 (44.7%) | 20 (5.1%) | 5–10 years | 219 (55.3%) | 17 (4.3%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 48 (12.1%) | 44 (11.1%) | ||||
| Medicines management by implication calls the clinician’s judgment into question | B/M Pharm | 87 (22%) | 0 (0%) | 0.000* | State funded | 181 (45.7%) | 18 (4.5%) | 0.031 | < 5 years | 59 (14.9%) | 9 (2.3%) | 0.021 |
| Pharm.D | 250 (63.1%) | 45 (11.4%) | Private | 165 (41.7%) | 32 (8.1%) | 5–10 years | 199 (50.2%) | 37 (9.3%) | ||||
| Overseas | 9 (2.3%) | 5 (1.3%) | – | – | – | > 10 years | 88 (22.2%) | 4 (1.0%) | ||||
| Medicines management challenges the clinician’s authority | B/M Pharm | 60 (15.2%) | 27 (6.8%) | 0.051 | State funded | 152 (38.4%) | 47 (11.9%) | 0.189 | < 5 years | 46 (11.6%) | 22 (5.6%) | 0.478 |
| Pharm.D | 217 (54.8%) | 78 (19.7%) | Private | 139 (35.1%) | 58 (14.6%) | 5–10 years | 177 (44.7%) | 59 (14.9%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 68 (17.2%) | 24 (6.1%) | ||||
| This enhanced clinical practice de-skills the clinicians/ practitioners | B/M Pharm | 48 (12.1%) | 39 (9.8%) | 0.000* | State funded | 154 (38.9%) | 45 (11.4%) | 0.000 | < 5 years | 62 (15.7%) | 6 (1.5%) | 0.000* |
| Pharm.D | 272 (68.7%) | 23 (5.8%) | Private | 180 (45.5%) | 17 (4.3%) | 5–10 years | 215 (54.3%) | 21 (5.3%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 57 (14.4%) | 35 (8.8%) | ||||
| I do not have time to discuss patient-related medicine issues with clinicians | B/M Pharm | 87 (22%) | 0 (0%) | 0.000* | State funded | 157 (39.6%) | 42 (10.6%) | 0.004 | < 5 years | 55 (13.9%) | 13 (3.3%) | 0.000* |
| Pharm.D | 232 (58.6%) | 63 (15.9%) | Private | 176 (44.4%) | 21 (5.3%) | 5–10 years | 187 (47.2%) | 49 (12.4%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 91 (23.0%) | 1 (0.3%) | ||||
| I feel inadequately trained to deal with clinicians on clinical medicine-related issues on behalf of patients | B/M Pharm | 87 (22%) | 0 (0%) | 0.000* | State funded | 193 (48.7%) | 6 (1.5%) | 0.000* | < 5 years | 59 (14.9%) | 9 (2.3%) | 0.055 |
| Pharm.D | 245 (61.9%) | 50 (12.6%) | Private | 153 (38.6%) | 44 (11.1%) | 5–10 years | 200 (50.5%) | 36 (9.1%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 87 (22.0%) | 5 (1.3%) | ||||
| I have sufficient confidence in my clinical knowledge to provide this service | B/M Pharm | 87 (22.0%) | 0 (0%) | 0.000* | State funded | 191 (48.2%) | 8 (2.0%) | 0.000* | < 5 years | 50 (12.6%) | 18 (4.5%) | 0.000* |
| Pharm.D | 208 (52.5) | 87 (22%) | Private | 118 (29.8%) | 79 (19.9%) | 5–10 years | 170 (42.9%) | 66 (16.7%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 89 (22.5%) | 3 (0.8%) | ||||
| Patients will get conflicting information regarding medicines use if pharmacists develop their medicines management services | B/M Pharm | 39 (9.8%) | 48 (12.1%) | 0.000* | State funded | 77 (19.4%) | 122 (30.8%) | 0.585 | < 5 years | 19 (4.8%) | 49 (12.4%) | 0.009 |
| Pharm.D | 95 (24%) | 200 (50.5%) | Private | 71 (17.9%) | 126 (31.8%) | 5–10 years | 83 (21.0%) | 153 (38.6%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 46 (11.6%) | 46 (11.6%) | ||||
| Enhanced clinical input will further develop my current relationship with clinicians | B/M Pharm | 51 (12.9%) | 36 (9.1%) | 0.000* | State funded | 162 (40.9%) | 37 (9.3%) | 0.001 | < 5 years | 66 (16.7%) | 2 (0.5%) | 0.000* |
| Pharm.D | 280 (70.7%) | 15 (3.8%) | Private | 183 (46.2%) | 14 (3.5%) | 5–10 years | 219 (55.3%) | 17 (4.3%) | ||||
| Overseas | 14 (3.5%) | 0 (0%) | – | – | – | > 10 years | 60 (15.2%) | 32 (8.1%) |
* = significant p-value with Cramer V